Evidence map›Paper›PMID 34165589›Full record

ArticleJournal of cancer research and clinical oncology2021

Retrospective analysis of cancer-specific gene expression panel for thyroid fine needle aspiration specimens.

Yongchun Wang, Brittany A McKelvey, Zhiyang Liu, Lisa Rooper, Leslie M Cope, Martha A Zeiger, Christopher B Umbricht

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cancer research and clinical oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.1field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Yongchun WangDepartment of Surgery, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Brittany A McKelveyDepartment of Surgery, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Zhiyang LiuDepartment of Surgery, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Lisa RooperDepartment of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Leslie M CopeDepartment of Oncology Biostatistics, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Martha A ZeigerSurgical Oncology Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Christopher B UmbrichtDepartment of Surgery, The Johns Hopkins University School of Medicine, Baltimore, MD, USA. cumbrich@jhmi.edu.ORCID http://orcid.org/0000-0002-1993-0553
Johns Hopkins University · USNational Institutes of Health · US

Funding

Training and Development of Outstanding Surgeon ScientistsZIEBC011992 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI ZEIGER, MARTHA · 2020 to 2024
$9.6M
Intramural NIH HHS ZIE BC011992Maryland Innovation Initiative #2016-MII-3379
6 · The paper itself

Abstract

backgroundWhile molecular testing is a promising strategy for preoperative assessment of cytologically indeterminate thyroid nodules, thyroid fine needle aspiration biopsy (FNA) presents unique challenges for molecular assays, including contaminating peripheral blood mononuclear cells (PBMC) and variable numbers of evaluable epithelial thyroid cells. Moreover, the newly recognized entity, noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP), has added an additional challenge to the currently available molecular diagnostic platforms. New diagnostic tools are still needed to correctly distinguish benign and malignant thyroid nodules preoperatively.

methodsTwenty-two transcript splice variants from 12 genes we previously identified as discriminating benign from malignant thyroid nodules were characterized in 80 frozen thyroid tumors from 8 histological subtypes. Isoforms detectable in PBMC were excluded, and the 5 most discriminating isoforms were further validated by real-time quantitative PCR (qPCR) on intraoperative FNA samples from 59 malignant tumors, 55 benign nodules, and 23 NIFTP samples. The qPCR threshold cycle values for each transcript were normalized to the thyrocyte-specific thyroid peroxidase isoform 1 (TPO1) and z-transformed. Receiver operating characteristic (ROC) analyses of the composite transcript scores were used to evaluate classification of thyroid FNAs by the 5-gene isoform expression panel.

resultsA molecular signature was developed by combining expression levels of specific isoforms of CDH3, FNDC4, HMGA2, KLK7, and PLAG1. FNAs containing at least 12-36 thyrocytes were sufficient for this assay. The 5-gene composite score achieved an area under the ROC curve (AUC) of 0.86 for distinguishing malignant from benign nodules, with a specificity of 91%, sensitivity of 75%, negative predictive value of 91%, and positive predictive value of 74%.

conclusionOur newly developed 5-gene isoform expression panel distinguishes benign from malignant thyroid tumors and, may help distinguish benign from malignant thyroid nodules in the context of the new NIFTP subtype.

Indexed as

AdolescentAdultAgedAged, 80 and overBiomarkers, TumorBiopsy, Fine-NeedleFemaleFollow-Up StudiesHumansLeukocytes, MononuclearMaleMiddle AgedMolecular Diagnostic TechniquesPrognosisRetrospective StudiesThyroid Cancer, PapillaryBiomarkers, TumorFine needle aspirationIndeterminate cytologyMolecular testThyrocyte-specific gene expressionThyroid cancer

Identifiers

PMID34165589
PMCPMC10087285
OpenAlexW3168265598

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.